— Know what they know.
Not Investment Advice

ZVRA NASDAQ

Zevra Therapeutics, Inc.
1W: -6.2% 1M: -13.7% 3M: -2.1% YTD: +14.3% 1Y: -10.8% 3Y: +118.1% 5Y: +1.4%
$10.05
+0.53 (+5.51%)
After Hours: $10.50 (+0.45, +4.48%)
Weekly Expected Move ±8.3%
$8 $9 $10 $11 $11
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 35 · $565.9M mcap · 54M float · 2.10% daily turnover · Short 64% of daily vol
Credit Risk of going bust: lower than 84% of companies Debt: 0.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Zevra Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.5M against a stock market value of $565.9M.
Distance to default 10.71 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $748K (short-term plus half of long-term), stock volatility 60.7%; Altman Z'' 4.62. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

📊 Key Metrics

TTM
$136M
Revenue
+119.4% YoY
$58M
Net Income
+2103.6% YoY
$33M
Free Cash Flow
+170.1% YoY
96.2%
Gross Margin
42.3%
Op. Margin
22.1%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE34.8%
ROA20.8%
ROIC-1356.4%

Valuation

P/E10.5
P/B2.7
EV/EBITDA9.0

Leverage

Debt/Equity0.01
Current Ratio5.17
Interest Cov.12.5x

Quality Scores

Piotroski F6/9
Altman Z6.50
Beneish M-1.71

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms